EFFICACY OF SUPPLEMENTATION OF PROBIOTICS ALONG WITH ANTIMICROBIAL AGENTS IN VULVOVAGINAL INFECTIONS IN A TERTIARY CARE HOSPITAL

Authors

  • DEEPA PATIL Department of Pharmacology, Basaveshwara Medical College and Hospital, SJMIT Campus, Chitradurga, Karnataka, India.
  • GEETHA S Department of Pharmacology, East Point College of Medical Sciences and Research Centre, Cheemasandra, Bidrahalli, Bengaluru, Karnataka,
  • RAGHUPRASADA MALLADAR SHIVAMURTHY Department of Pharmacology, S S Institute of Medical Sciences and Research Center, Davangere, Karnataka, India.
  • UMAKANT N PATIL Department of Pharmacology, Basaveshwara Medical College and Hospital, SJMIT Campus, Chitradurga, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i12.43269

Keywords:

Vulvovaginal infections, Trichomoniasis, Candidiasis, Bacterial vaginosis, Probiotics, Antimicrobial agents

Abstract

Objectives: The objectives of the study were to ascertain the efficacy of probiotics along with antimicrobials in the treatment of vulvovaginitis and to evaluate the rate of recurrence.

Methods: The study was done on 60 patients who were randomly selected and divided into two groups of 30 each. Prior permission from the Institutional Ethics Committee and higher authorities was obtained before conducting the study. One group received standard treatment including antibacterial, antiviral, and antifungal as per the gynecologist discretion and in other group along with standard treatment, probiotic capsules containing combination of Saccharomyces boulardii, Lactobacillus sporogenes (50 million), Streptococcus faecalis (30 million), Clostridium butyricum (2 million), and Bacillus mesentericus (1 million) given orally twice daily and followed up for a period of 3 months. The drugs were started on the 5th day after menstruation taking starting of the bleeding as day 1.

Results: The parameters compared were symptoms and signs (significantly reduced – p-value), clue cells (significantly reduced in number), and recurrence rates (significantly reduced), in 80% of patients smears which were not consistent with BV. Maximum number of patients showed negative KOH mount (71.5%), saline wet mount was negative in 80% of patients in antimicrobial agents + probiotics group.

Conclusion: From the present interventional study, probiotics along with antimicrobial agents showed better improvement than antimicrobial agents alone. Hence, supplementation of probiotics along with antimicrobial agents provides better efficacy than antimicrobial agents alone in treating vulvovaginal infections.

Downloads

Download data is not yet available.

References

Mastromarino P, Vitali B, Mosca L. Bacterial vaginosis: A review on clinical trials with probiotics. New Microbiol 2013;36:229-38.

Cannoni BG, Borquez RS. Vavlovaginitis and sexually transmitted infections in adolescence. Rev Med Clin Condes 2011;22:49-57.

Santos AR, Pereiro M Jr., Toribio J. Recurrent vulvovaginitis: Diagnostic assessment and therapeutic management. Actas Dermosifiliogr 2008;99:190-8.

Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009;4:CD006289.

Larsson PG, Bergstrom M, Forsum U, Jacobsson B, Strand A, Wolner-Hanseen P. Bacterial vaginosis. Transmission, role in genital tract infection and pregnancy outcome: An enigma. APMIS 2005;113:233-45.

Eriksson K, Carlsson B, Forsum U, Larsson PG. A double blind treatment study of bacterial vaginosis with normal vaginal Lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm Venereol 2005;85:42-6.

Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: A double blind randomized, placebo controlled study. Am J Obstet Gynaecol 2010;203:120-5.

Vicariotto F, Del Piano M, Mogna L, Mogna G. Effectiveness of the association of two probiotic strains formulated in a slow release vaginal product, in women affected by vuvlovaginal candidiasis: A pilot study. J Clin Gastroenterol 2012;46:S73-80.

Martinez RC, Franceschini SA, Patta MC, Quintana SM, Candido RC, Ferreira JC, et al., Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol 2009;48:269-74.

Xie HY, Feng D, Wei DM, Chen H, Mei L, Wang F, et al. Probiotics for vuvlovaginal candidiasis in non pregnant women. Cochrane 2013;4:1-63.

Cribby S, Taylor M, Reid G. Vaginal microbiota and the use of probiotics. Inetrdiscip Perspect Infect Dis 2008;2008:256490.

Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osmene G, Bruce AW, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: Randomized, double blind, placebo controlled trial. Microbes Infect 2006;8:1450-4.

Division of AIDS table for Grading the Severity of Adult and Pediatric Adverse Events. Published Date: December 2004. Available from: http:// www.rsc.tech_res.com/Documents/Safetyandpharmacovigilance/ Addendum_1_Female_Genital Grading_Table_V1_Nov 2007.Pdf

Waigankar SS, Patel M. Role of probiotics in urogenital health. J Med Health 2012;2:5-10.

Nouraei S, Akbari SA, Jorjani M, Majd HA, Afrakhteh M, Ghafoorian A, et al. Comparison between fluconazole with oral protexin combination and fluconazole in the treatment of vulvovaginal candidiasis. Obstet Gynecol 2012;2012:375806.

Published

07-12-2021

How to Cite

PATIL, D., G. S, R. M. SHIVAMURTHY, and U. N PATIL. “EFFICACY OF SUPPLEMENTATION OF PROBIOTICS ALONG WITH ANTIMICROBIAL AGENTS IN VULVOVAGINAL INFECTIONS IN A TERTIARY CARE HOSPITAL”. Asian Journal of Pharmaceutical and Clinical Research, vol. 14, no. 12, Dec. 2021, pp. 119-22, doi:10.22159/ajpcr.2021.v14i12.43269.

Issue

Section

Original Article(s)